A Phase I, Open-Label Study To Determine The Maximum Tolerated Dose (Mtd) Of The Combination Of Lenalidomide And Cetuximab, And To Evaluate The Efficacy Of This Combination In Subjects With Wild Type K-Ras Metastatic Colorectal Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2012
At a glance
- Drugs Cetuximab (Primary) ; Lenalidomide (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2011 Planned end date changed from 1 Oct 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 01 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.